Stockscreener 앱 받기
161.09
1.73%
3.09
전일 마감가:
$158.00
열려 있는:
$154.09
하루 거래량:
1.17M
Relative Volume:
1.35
시가총액:
$7.91B
수익:
$4.02B
순이익/손실:
$-79.62M
주가수익비율:
-103.59
EPS:
-1.5551
순현금흐름:
$543.67M
1주 성능:
+1.26%
1개월 성능:
-26.84%
6개월 성능:
+1.43%
1년 성능:
-2.58%
1일 변동 폭
$151.31
$160.99
1주일 범위
$146.33
$164.36
52주 변동 폭
$91.86
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
160.82 | 7.78B | 4.02B | -79.62M | 543.67M | -1.5551 |
|
TMO
Thermo Fisher Scientific Inc
|
512.87 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
210.12 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
628.91 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.77 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
330.51 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative - simplywall.st
Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript - Insider Monkey
CenterBook Partners LP Raises Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Strategic Review at Charles River Laboratories Raises Deal Uncertainty, Execution Risks, and Shareholder Value Concerns - TipRanks
Decoding Charles River Laboratories International Inc (CRL): A S - GuruFocus
Charles River Laboratories (CRL) Exceeds Q4 Revenue Expectations with Strategic Growth - GuruFocus
Charles River (CRL) Anticipates Steady Revenue Growth through FY - GuruFocus
The Bull Case For Charles River Laboratories (CRL) Could Change Following 2025 Losses And New Leadership Appointments - Yahoo Finance
Charles River Laboratories (CRL) Appoints New Chief Financial Of - GuruFocus
Glenn Coleman and Kerry Dailey to join Charles River Labs leadership By Investing.com - Investing.com South Africa
Why Charles River Labs Stock Is Sliding Today - TipRanks
Charles River Labs Eyes Margin Gains Amid Flat Growth - TipRanks
Charles River Labs Appoints Glenn Coleman as New CFO - TipRanks
Charles River Laboratories International Inc (CRL) Q4 2025 Earni - GuruFocus
Charles River projects up to 9% EPS growth in 2026 as new CEO, acquisitions, and cost savings drive margin expansion - MSN
Glenn Coleman and Kerry Dailey to join Charles River Labs leadership - Investing.com Nigeria
Charles River Laboratories International (NYSE:CRL) Shares Gap DownWhat's Next? - MarketBeat
JPMorgan Cuts Charles River Laboratories International Price Target to $165 From $190, Maintains Neutral Rating - marketscreener.com
Charles River Lab Taps Veteran Atty For New CLO Post - Law360
Charles River Laboratories Q4 2025 earnings preview - MSN
C-suite changes continue at Charles River with new CFO, legal chief - The Business Journals
Charles River Laboratories International Q4 Earnings Call Highlights - MarketBeat
Laboratory Giant Charles River Reels-in Alcon Lawyer for New CLO Post - Law.com
New Charles River Leaders May Shape Valuation, Debt And Governance Outlook - simplywall.st
Charles River Laboratories International, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Charles River Laboratories Q4 Review: Approaching A Bottom (NYSE:CRL) - Seeking Alpha
CRL: 2026 outlook projects margin and EPS growth, with DSA recovery and cost savings offsetting early headwinds - TradingView
Charles River (CRL) Earnings Call Transcript - AOL.com
Charles River Laboratories Announces Executive Appointments - PharmiWeb.com
Charles River Laboratories International (NYSE:CRL) Issues Quarterly Earnings Results - MarketBeat
Charles River Laboratories International (NYSE:CRL) Issues FY 2026 Earnings Guidance - MarketBeat
Charles River Laboratories (CRL) Q4 revenue, adjusted earnings top expectations - AlphaStreet News
Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings - Yahoo Finance
Charles River Laboratories International, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 27, 2025 - marketscreener.com
CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise - TradingView
Charles River Laboratories International, Inc. Announces Chief Financial Officer Changes, Effective April 6, 2026 - marketscreener.com
Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations - Finviz
Charles River: Q4 Earnings Snapshot - KVUE
Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Charles River forecasts upbeat 2026 profit on improved demand for drug development services - marketscreener.com
Charles River Q4 Adjusted Earnings, Revenue Decline; New CFO Named - marketscreener.com
CHARLES RIVER LABS INTL ($CRL) Releases Q4 2025 Earnings - Quiver Quantitative
Charles River Laboratories 8-K Filing Analysis - TradingView
Charles River Laboratories earnings beat by $0.04, revenue topped estimates - Investing.com Canada
CRL: Non-cash impairments drove GAAP losses, but 2026 guidance anticipates EPS growth - TradingView
Charles River Laboratories announces executive appointments - marketscreener.com
Charles River Labs beats Q4 expectations, provides cautious 2026 outlook - Investing.com
Charles River names Glenn Coleman as CFO, Kerry Dailey as CLO - StreetInsider
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance - Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) Q4 2025 earnings call transcript - MSN
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
3.28%
자본화:
|
볼륨(24시간):